Lactoferrin - Pharming
Alternative Names: GPX 400; hLFLatest Information Update: 11 Dec 2021
Price :
$50 *
At a glance
- Originator Pharming Group NV
- Class Adjuvants; Antibacterials; Antifungals; Glycoproteins; Iron binding proteins
- Mechanism of Action Chelating agents; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Bacterial infections; Cardiovascular disorders; Eye disorders; Haemorrhage; Hepatitis C
Most Recent Events
- 08 Mar 2005 Pharming and ProBio and Infigen have entered into an agreement for lactoferrin
- 28 Oct 2003 Lactoferrin is no longer licensed to AM-Pharma Holding
- 31 Mar 2003 Pharming has developed a focussed strategy for further development of its lactoferrin product that will be pursued through strategic partnerships with interested parties. As such, the product is available for licensing (http://pharming.com)